GE Healthcare and Janssen to Develop Biosignatures for Alzheimer’s Disease
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 10 (Table of Contents)
Published: 17 Dec-2010
DOI: 10.3833/pdr.v2010.i10.1411 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
GE Healthcare and Janssen Pharmaceutica have signed a research deal to develop biosignatures (combinations of biomarkers) to identify Alzheimer’s disease prior to the onset of clinical symptoms...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS